Regulus Therapeutics Inc [RGLS] stock is trading at $8.21, up 0.12%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RGLS shares have gain 0.74% over the last week, with a monthly amount glided 4.32%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regulus Therapeutics Inc [NASDAQ: RGLS] stock has seen the most recent analyst activity on March 27, 2025, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $6 from $3. Previously, Oppenheimer started tracking the stock with Outperform rating on August 02, 2024, and set its price target to $7. On March 18, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $6 on the stock. B. Riley FBR Inc. started tracking the stock assigning a Neutral rating and suggested a price target of $1 on March 28, 2018. Leerink Partners initiated its recommendation with a Outperform and recommended $2 as its price target on January 05, 2018. Chardan Capital Markets reiterated a Buy rating for this stock on June 13, 2017, and downed its price target to $2.50. In a note dated March 06, 2017, Wedbush reiterated an Outperform rating on this stock and revised its target price from $8 to $6.
Regulus Therapeutics Inc [RGLS] stock has fluctuated between $0.83 and $8.35 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Regulus Therapeutics Inc [NASDAQ: RGLS] shares were valued at $8.21 at the most recent close of the market. An investor can expect a potential drop of -14.74% based on the average RGLS price forecast.
Analyzing the RGLS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -0.58 and Total Capital is -0.73. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.16 points at the first support level, and at 8.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.28, and for the 2nd resistance point, it is at 8.34.
Ratios To Look Out For
For context, Regulus Therapeutics Inc’s Current Ratio is 15.52. In addition, the Quick Ratio stands at 15.52 and the Cash Ratio stands at 11.25.
Transactions by insiders
Recent insider trading involved Klassen Preston, President & Head of R & D, that happened on Jun 03 ’25 when 12000.0 shares were purchased. Chief Executive Officer, Hagan Joseph P completed a deal on Jan 30 ’25 to buy 50000.0 shares. Meanwhile, Director BALTIMORE DAVID bought 19610.0 shares on Jan 30 ’25.
